CL2019003107A1 - Compuestos heterocíclicos bicíclicos sustituidos utilizados como inhibidores de nadph oxidasa. - Google Patents
Compuestos heterocíclicos bicíclicos sustituidos utilizados como inhibidores de nadph oxidasa.Info
- Publication number
- CL2019003107A1 CL2019003107A1 CL2019003107A CL2019003107A CL2019003107A1 CL 2019003107 A1 CL2019003107 A1 CL 2019003107A1 CL 2019003107 A CL2019003107 A CL 2019003107A CL 2019003107 A CL2019003107 A CL 2019003107A CL 2019003107 A1 CL2019003107 A1 CL 2019003107A1
- Authority
- CL
- Chile
- Prior art keywords
- compounds
- compounds used
- heterocyclic compounds
- nadph oxidase
- bicyclic heterocyclic
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 108010002998 NADPH Oxidases Proteins 0.000 title abstract 2
- 102000004722 NADPH Oxidases Human genes 0.000 title abstract 2
- 125000002618 bicyclic heterocycle group Chemical group 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 102100021217 Dual oxidase 2 Human genes 0.000 abstract 1
- 101000968308 Homo sapiens Dual oxidase 1 Proteins 0.000 abstract 1
- 101000968305 Homo sapiens Dual oxidase 2 Proteins 0.000 abstract 1
- 102000004316 Oxidoreductases Human genes 0.000 abstract 1
- 108090000854 Oxidoreductases Proteins 0.000 abstract 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
LA PRESENTE INVENCIÓN SE REFIERE A COMPUESTOS DE HETEROARILO Y HETEROCÍCLICOS FUSIONADOS SUSTITUIDOS, ÚTILES COMO INHIBIDORES DE LA NICOTINAMIDA ADENINA DINUCLEÓTIDO FOSFATO OXIDASA (INHIBIDORES DE LA NADPH OXIDASA), PROCESOS PARA SU PREPARACIÓN, COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN LOS COMPUESTOS, Y EL USO DE LOS COMPUESTOS O LAS COMPOSICIONES EN EL TRATAMIENTO O PREVENCIÓN DE DIVERSAS ENFERMEDADES, AFECCIONES Y/O TRASTORNOS MEDIADOS POR LA NADPH OXIDASA.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201721015787 | 2017-05-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2019003107A1 true CL2019003107A1 (es) | 2020-03-13 |
Family
ID=62245373
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2019003107A CL2019003107A1 (es) | 2017-05-04 | 2019-10-29 | Compuestos heterocíclicos bicíclicos sustituidos utilizados como inhibidores de nadph oxidasa. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20200247800A1 (es) |
| EP (1) | EP3619209A1 (es) |
| JP (1) | JP2020518624A (es) |
| KR (1) | KR20200013665A (es) |
| CN (1) | CN110914263A (es) |
| AU (1) | AU2018262528A1 (es) |
| BR (1) | BR112019023109A2 (es) |
| CA (1) | CA3062185A1 (es) |
| CL (1) | CL2019003107A1 (es) |
| CO (1) | CO2019013655A2 (es) |
| EA (1) | EA201992343A1 (es) |
| MX (1) | MX2019013148A (es) |
| PE (1) | PE20191789A1 (es) |
| PH (1) | PH12019502462A1 (es) |
| SG (1) | SG11201910172VA (es) |
| WO (1) | WO2018203298A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113423711B (zh) | 2018-10-01 | 2024-03-15 | 建新公司 | 作为udp糖基转移酶抑制剂的噻吩并[3,2-b]吡啶衍生物及其使用方法 |
| CN115215767B (zh) * | 2021-04-16 | 2023-09-12 | 帕潘纳(北京)科技有限公司 | 制备2-氰基-3-乙氧基丙烯酸乙酯衍生物的方法 |
| CN113292496B (zh) * | 2021-05-17 | 2023-03-10 | 安徽联创生物医药股份有限公司 | 一种劳拉替尼中间体的合成方法 |
| US20240294920A1 (en) * | 2021-07-01 | 2024-09-05 | Ionis Pharmaceuticals, Inc. | Modulation of nox4 expression |
| US20260021079A1 (en) | 2022-05-09 | 2026-01-22 | Calliditas Therapeutics Suisse Sa | Nox inhibitors for use in the treatment of alport syndrome |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1616576A4 (en) * | 2003-04-08 | 2010-02-10 | Mitsubishi Tanabe Pharma Corp | SPECIFIC NAD (P) H OXIDASE HEMMER |
| JP2007133750A (ja) * | 2005-11-11 | 2007-05-31 | Canon Inc | 情報処理方法及び情報処理装置 |
| EP2002835A1 (en) | 2007-06-04 | 2008-12-17 | GenKyo Tex | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
| FR2929276B1 (fr) * | 2008-04-01 | 2010-04-23 | Servier Lab | Nouveaux derives de diosmetine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| EP2166009A1 (en) | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as nadph oxidase inhibitors |
| EP2166008A1 (en) | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
| EP2166010A1 (en) * | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
| EP2165707A1 (en) | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
| GB201104600D0 (en) * | 2011-03-18 | 2011-05-04 | Pronoxis Ab | New compounds and medical uses |
| WO2017091585A1 (en) * | 2015-11-25 | 2017-06-01 | Effector Therapeutics, Inc. | Eif4-a-inhibiting compounds and methods related thereto |
-
2018
- 2018-05-04 MX MX2019013148A patent/MX2019013148A/es unknown
- 2018-05-04 PE PE2019002276A patent/PE20191789A1/es unknown
- 2018-05-04 CA CA3062185A patent/CA3062185A1/en not_active Abandoned
- 2018-05-04 WO PCT/IB2018/053121 patent/WO2018203298A1/en not_active Ceased
- 2018-05-04 KR KR1020197035127A patent/KR20200013665A/ko not_active Withdrawn
- 2018-05-04 US US16/610,351 patent/US20200247800A1/en not_active Abandoned
- 2018-05-04 EA EA201992343A patent/EA201992343A1/ru unknown
- 2018-05-04 JP JP2019560286A patent/JP2020518624A/ja active Pending
- 2018-05-04 AU AU2018262528A patent/AU2018262528A1/en not_active Abandoned
- 2018-05-04 SG SG11201910172V patent/SG11201910172VA/en unknown
- 2018-05-04 EP EP18727437.8A patent/EP3619209A1/en not_active Withdrawn
- 2018-05-04 CN CN201880044473.8A patent/CN110914263A/zh active Pending
- 2018-05-04 BR BR112019023109-9A patent/BR112019023109A2/pt not_active Application Discontinuation
-
2019
- 2019-10-29 CL CL2019003107A patent/CL2019003107A1/es unknown
- 2019-10-31 PH PH12019502462A patent/PH12019502462A1/en unknown
- 2019-12-03 CO CONC2019/0013655A patent/CO2019013655A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112019023109A2 (pt) | 2020-05-26 |
| PH12019502462A1 (en) | 2020-06-29 |
| CO2019013655A2 (es) | 2020-04-01 |
| CA3062185A1 (en) | 2018-11-08 |
| SG11201910172VA (en) | 2019-11-28 |
| KR20200013665A (ko) | 2020-02-07 |
| EA201992343A1 (ru) | 2020-04-16 |
| JP2020518624A (ja) | 2020-06-25 |
| EP3619209A1 (en) | 2020-03-11 |
| WO2018203298A1 (en) | 2018-11-08 |
| MX2019013148A (es) | 2019-12-18 |
| US20200247800A1 (en) | 2020-08-06 |
| AU2018262528A1 (en) | 2019-11-21 |
| CN110914263A (zh) | 2020-03-24 |
| PE20191789A1 (es) | 2019-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019003107A1 (es) | Compuestos heterocíclicos bicíclicos sustituidos utilizados como inhibidores de nadph oxidasa. | |
| CO2018013978A2 (es) | Derivados de ácido borónico y usos terapéuticos de los mismos. | |
| CO2017011535A2 (es) | Composiciones de ácido obeticólico y métodos de uso | |
| CO2017011851A2 (es) | Compuestos novedosos | |
| HK1245777A1 (zh) | 用作nadph氧化酶抑制剂的氨基噻二唑衍生物 | |
| CO2017008403A2 (es) | Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos | |
| UY36265A (es) | “derivados de pirrolo[2,3-d]pirimidina”. | |
| CL2016001895A1 (es) | Compuestos | |
| MX374191B (es) | Derivados de nucleósido sustituidos con 4´ -difluorometilo como inhibidores de la replicación de arn de la influenza. | |
| CR20190446A (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral de dengue | |
| EA201692422A1 (ru) | Состав, содержащий пролекарство гемцитабина | |
| CU20190101A7 (es) | Imidazopirimidinas diazabicíclicas sustituidas | |
| UY37742A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| MX375099B (es) | Derivados de aminotiazol útiles como agentes antivíricos. | |
| CL2022000758A1 (es) | Tienopirimidonas como inhibidores de trpa1 | |
| MX2017013137A (es) | Derivados de cromeno como inhibidores de las fosfoinositido-3-cina sas. | |
| MX2020003495A (es) | Derivados de acido boronico y sintesis de los mismos. | |
| CL2022000757A1 (es) | Tienopirimidonas como inhibidores de trpa1 | |
| DOP2019000221A (es) | Derivados de pirazol como inhibidores de bromodominio | |
| UY37555A (es) | Derivados de ácido piridin-3-il-acético como inhibidores de la replicación del virus de la inmunodeficiencia humana | |
| BR112017009850A2 (pt) | composto, composição, e, uso de uma quantidade melhoradora de hiv de um composto | |
| MX375545B (es) | Derivados de piridazinona como inhibidores de las fosfoinositido-3-cinasas. | |
| MX2021011979A (es) | Derivados del isocromeno como inhibidores de la fosfoinositida 3-cinasa. | |
| EA201890826A1 (ru) | Конденсированные производные пиридина в качестве ингибиторов киназы | |
| BR112017009852A2 (pt) | composto, composição, e, usos de um composto |